Robotic Surgery Comes of Age in the Most Radical Operation for Rectal Cancer

Pelvic exenteration is one of the most formidable operations in all of surgery. It involves removing the rectum together with the bladder, the internal reproductive organs, and sometimes parts of the bony pelvis, in a single en bloc resection designed to eliminate a tumor that has grown beyond the bowel wall and invaded neighboring structures. For patients with locally advanced rectal cancer that has spread into the pelvic organs, this multivisceral procedure may represent the only realistic chance of cure. Now, a large multicenter study from Japan reports that this operation, long performed exclusively through large open incisions, is increasingly being carried out with surgical robots, and that the robotic approach can be delivered with remarkably encouraging short-term outcomes in carefully selected patients.

The new analysis, published in Annals of Gastroenterological Surgery, drew on data from 26 Japanese institutions affiliated with the Japan Society for Endoscopic Surgery, the Japan Society of Obstetrics and Gynecology, and the Japan Society of Endourology and Robotics, each of which had performed at least one robot-assisted pelvic exenteration for a pelvic malignancy. Between January 2012 and October 2022, 135 patients underwent pelvic exenteration for primary rectal cancer across these centers. Of these, 57 operations were performed laparoscopically, 35 were open procedures, and 43 were robot-assisted. The researchers, led by Shoma Yamamoto and colleagues, focused their secondary analysis on this robotic cohort, describing who was selected for the approach, how safely it was implemented, and how its use evolved over the decade of the study.

The patients chosen for robotic exenteration were, by any measure, facing advanced disease. Ninety-eight percent had clinical T4 tumors, meaning the cancer had grown directly into adjacent organs or structures. Seventy-nine percent had cancer that had spread to nearby lymph nodes, and 16 percent already had distant metastases at diagnosis, typically treated with neoadjuvant chemotherapy before surgery. The median age was 66 years, 84 percent were men, and nearly a quarter had an American Society of Anesthesiologists physical status score of 3 or higher, indicating severe systemic illness. Total pelvic exenteration, the most extensive variant involving removal of the rectum, distal colon, and all genitourinary viscera, accounted for 61 percent of the robotic cases, demonstrating that the robotic platform was not being reserved for the simpler, organ-preserving subtypes of the operation.

The perioperative results are the heart of the report. Among the 43 robotic patients, the median operative time was 690 minutes, nearly twelve hours on the table, underscoring the sheer complexity of the procedure. Yet the median intraoperative blood loss was just 360 milliliters, a striking figure for an operation of this magnitude. Only 30 percent of robotic patients required an intraoperative blood transfusion, and among those who did, the median transfused volume was a mere 280 milliliters. By comparison, in the open surgery cohort the median blood loss was 2,081 milliliters and 77 percent of patients needed transfusions. This matters clinically because perioperative transfusion has been linked in previous research to higher postoperative morbidity and worse long-term outcomes after colorectal cancer surgery, giving surgeons a concrete reason to favor techniques that minimize bleeding.

Oncological quality of the resection was equally impressive. Achieving an R0 resection, meaning complete removal of the tumor with no microscopic residual disease at the margins, is the single most important determinant of long-term survival after pelvic exenteration. In the robotic cohort, 42 of 43 patients, or 98 percent, achieved R0 resection, with only one patient left with microscopic residual tumor and none with gross residual disease. Within 30 days of surgery, complications of Clavien-Dindo Grade II or higher occurred in 37 percent of robotic patients, most commonly organ-space surgical site infections and ileus, each affecting five patients. More serious Grade III or higher complications arose in 16 percent. Crucially, not a single robotic patient required reoperation during hospitalization, and there were no deaths within 30 days of surgery. The median postoperative hospital stay was 23 days, notably shorter than the 34 days observed after both open and laparoscopic exenteration in the same cohort.

Perhaps the most telling finding is how rapidly the robotic approach took hold once it was introduced. The first robot-assisted pelvic exenteration in this cohort was performed in 2019, with five procedures that year, rising to six in 2020, thirteen in 2021, and nineteen by October 2022. By 2021 the robotic approach had become the most frequently used technique across the participating institutions, and in 2022 it accounted for 19 of the 26 pelvic exenterations performed, or 73 percent. The authors are careful to note that this rapid adoption should not be read as proof that the robot has replaced open or laparoscopic surgery, since shifts in patient selection, robotic platform availability, institutional experience, and referral patterns all influence which approach is chosen. Still, the trajectory reveals how quickly Japanese surgical centers integrated the technology into one of the most demanding operations they perform.

Why might the robot confer an advantage in the pelvis specifically? The surgical robot offers three-dimensional, magnified visualization of the operative field, articulated instruments with seven degrees of freedom that can far exceed the range of the human wrist, tremor filtration, motion scaling that converts large hand movements into precise micro-movements, and a stable endoscopic platform that eliminates camera shake. In the confined, bony confines of the pelvis, where the rectum sits amid the bladder, reproductive organs, major vessels, and the sacrum, these features may allow surgeons to dissect more precisely along tumor planes and secure hemostasis more effectively than is possible with conventional laparoscopic instruments. Previous studies have similarly reported lower blood loss with minimally invasive pelvic exenteration compared with open surgery, and the present findings are consistent with that pattern.

The authors are appropriately cautious about what these results do and do not prove. Because the study is retrospective and surgeons chose each patient’s approach based on tumor anatomy, technical feasibility, and institutional experience, the comparison between approaches is vulnerable to confounding by indication. Patients selected for robotic surgery may have had less extensive pelvic sidewall fixation, less fibrosis or inflammation, less vascular involvement, or lower reconstructive complexity than those directed to open surgery, and the study did not uniformly collect these anatomical details. Supplementary propensity score-matched analyses, which paired patients with similar measured characteristics, suggested favorable perioperative profiles for the robotic approach, but the researchers explicitly designated these analyses as exploratory and hypothesis-generating rather than definitive evidence of superiority. The high R0 rate, likewise, reflects successful resection in patients judged suitable for a minimally invasive attempt, not a demonstration that the robot outperforms the open approach oncologically.

The report also carries practical lessons for surgical programs considering the technology. Pelvic exenteration demands capabilities well beyond standard robot-assisted rectal resection: multivisceral dissection, urinary reconstruction, in this cohort 81 percent of robotic patients required ileal conduit diversion, intestinal reconstruction, complex intraoperative decision-making, and coordination across surgical specialties. Prior research suggests roughly 30 cases are needed to overcome the learning curve in routine robotic colorectal surgery, but exenteration is far more heterogeneous, and experience with standard procedures does not translate automatically. The authors recommend that robot-assisted exenteration be introduced cautiously at institutions with established expertise in both robotic surgery and open pelvic exenteration, supported by a mature perioperative care system.

The overall message is one of complementarity rather than replacement. Robot-assisted pelvic exenteration appears feasible and safe for selected patients with primary rectal cancer, offering dramatically reduced blood loss, a near-universal R0 rate, no 30-day mortality, and shorter hospital stays in this Japanese multicenter experience. Yet open surgery remains essential when wide exposure, rapid vascular control, extensive bony resection such as sacrectomy, severe pelvic sepsis, or major vascular involvement is anticipated; only six patients in the entire cohort, and just one robotic patient, underwent bony excision, so the most technically extreme cases remain largely outside the robotic experience. The operative approach, the authors conclude, should be individualized according to tumor anatomy, technical feasibility, and institutional capability. Longer follow-up will be needed to establish whether the encouraging short-term outcomes translate into superior survival, but for a procedure once considered the exclusive domain of open surgery, the robotic era has clearly arrived.

Subject of Research: Robot-assisted pelvic exenteration for primary rectal cancer

Article Title: Clinical Implementation and Perioperative Outcomes of Robot‐Assisted Pelvic Exenteration for Primary Rectal Cancer: A Multicenter Japanese Experience

Article References: Yamamoto, S., Kagawa, H., Yatabe, Y., & Kinugasa, Y. (2026). Clinical Implementation and Perioperative Outcomes of Robot‐Assisted Pelvic Exenteration for Primary Rectal Cancer: A Multicenter Japanese Experience. Annals of Gastroenterological Surgery, Article ags3.70296. https://doi.org/10.1002/ags3.70296

Image Credits: AI Generated

DOI: 10.1002/ags3.70296

Keywords: rectal cancer, pelvic exenteration, robotic surgery, minimally invasive surgery, R0 resection, surgical outcomes, Japan, multicenter study, T4 tumors, blood loss, perioperative complications, surgical oncology